» Articles » PMID: 38330910

Membrane Permeability in a Large Macrocyclic Peptide Driven by a Saddle-Shaped Conformation

Abstract

The effort to modulate challenging protein targets has stimulated interest in ligands that are larger and more complex than typical small-molecule drugs. While combinatorial techniques such as mRNA display routinely produce high-affinity macrocyclic peptides against classically undruggable targets, poor membrane permeability has limited their use toward primarily extracellular targets. Understanding the passive membrane permeability of macrocyclic peptides would, in principle, improve our ability to design libraries whose leads can be more readily optimized against intracellular targets. Here, we investigate the permeabilities of over 200 macrocyclic 10-mers using the thioether cyclization motif commonly found in mRNA display macrocycle libraries. We identified the optimal lipophilicity range for achieving permeability in thioether-cyclized 10-mer cyclic peptide-peptoid hybrid scaffolds and showed that permeability could be maintained upon extensive permutation in the backbone. In one case, changing a single amino acid from d-Pro to d-NMe-Ala, representing the loss of a single methylene group in the side chain, resulted in a highly permeable scaffold in which the low-dielectric conformation shifted from the canonical cross-beta geometry of the parent compounds into a novel saddle-shaped fold in which all four backbone NH groups were sequestered from the solvent. This work provides an example by which pre-existing physicochemical knowledge of a scaffold can benefit the design of macrocyclic peptide mRNA display libraries, pointing toward an approach for biasing libraries toward permeability by design. Moreover, the compounds described herein are a further demonstration that geometrically diverse, highly permeable scaffolds exist well beyond conventional drug-like chemical space.

Citing Articles

Chromatographic Determination of Permeability-Relevant Lipophilicity Facilitates Rapid Analysis of Macrocyclic Peptide Scaffolds.

Koch G, Engstrom A, Taechalertpaisarn J, Faris J, Ono S, Naylor M J Med Chem. 2024; 67(21):19612-19622.

PMID: 39453819 PMC: 11571107. DOI: 10.1021/acs.jmedchem.4c01956.


Selection of Nucleotide-Encoded Mass Libraries of Macrocyclic Peptides for Inaccessible Drug Targets.

Colas K, Bindl D, Suga H Chem Rev. 2024; 124(21):12213-12241.

PMID: 39451037 PMC: 11565579. DOI: 10.1021/acs.chemrev.4c00422.

References
1.
Driver R, Hoang H, Abbenante G, Fairlie D . A cyclic beta-strand tripeptide with an alpha-helix like CD spectrum. Org Lett. 2009; 11(14):3092-5. DOI: 10.1021/ol901181b. View

2.
White T, Renzelman C, Rand A, Rezai T, McEwen C, Gelev V . On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds. Nat Chem Biol. 2011; 7(11):810-7. PMC: 3210067. DOI: 10.1038/nchembio.664. View

3.
Linker S, Schellhaas C, Ries B, Roth H, Fouche M, Rodde S . Polar/apolar interfaces modulate the conformational behavior of cyclic peptides with impact on their passive membrane permeability. RSC Adv. 2022; 12(10):5782-5796. PMC: 8981571. DOI: 10.1039/d1ra09025a. View

4.
Perczel A, Hollosi M, Sandor P, Fasman G . The evaluation of type I and type II beta-turn mixtures. Circular dichroism, NMR and molecular dynamics studies. Int J Pept Protein Res. 1993; 41(3):223-36. DOI: 10.1111/j.1399-3011.1993.tb00330.x. View

5.
Oh M, Lee H, Jo S, Park B, Park S, Kim E . Development of Cassette PAMPA for Permeability Screening. Biol Pharm Bull. 2017; 40(4):419-424. DOI: 10.1248/bpb.b16-00755. View